ClinicalTrials.gg
CompletedNCT07168824Updated Sep 25, 2026

An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition

An interventional study of Lacticaseibacillus paracasei in Subjective Cognitive Decline (SCD), sponsored by Chi-Chang Huang. Completed at 1 site in Taiwan. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Chi-Chang Huang · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Cognitive Dysfunction with a site in Taiwan — 24 open to participants now, 29 under way, 3 of them phase 3. Cognitive Dysfunction · Taiwan.

Enrollment
69th of 94
40 · median 62
Started
2025
with 13 others
No phase
78 of 111
15 open now
Registered
98th of 111
by date

Among the 111 studies in Cognitive Dysfunction with a site in Taiwan, this one is the 69th largest by enrollment of the 94 interventional ones that give a count, is one of 14 that started in 2025, is one of 78 with no phase, and was the 98th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

24 of the 111 studies in Cognitive Dysfunction with a site in Taiwan are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Cognitive Dysfunction with a site in Taiwan, or all of them as a file.
02

Study summary

This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.

Read the detailed description

Lacticaseibacillus paracasei PS23 (PS23) is a specific strain of probiotic bacteria known for its potential health benefits, particularly in the context of aging and muscle health. Research suggests that it may improve cognitive function, reduce age-related muscle loss, and modulate the gut microbiota. Probiotic supplements like PS23 are being explored as potential therapeutic agents for age-related cognitive deficits. A prior study showed that PS23 supplementation delayed age-related cognitive decline in mice. Additionally, PS23 has shown antidepressant-like effects and has been found to enhance physical performance and promote muscle recovery following injury.

03

Conditions studied

  • Subjective Cognitive Decline (SCD)

Keywords

  • Subjective Cognitive Decline
  • Mild cognitive impairment
  • probiotics
  • dietary supplement
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50 to 85 years who self-report experiencing signs of cognitive decline.
  • No prior diagnosis of dementia or Alzheimer's disease (AD).
  • Willing and able to comply with study assessments and requirements, and provide written .

Exclusion criteria

Exclusion Criteria:

  • Use of antibiotics or probiotic powder, capsules, or tablets within the past month.
  • Currently undergoing antibiotic treatment.
  • Known allergy to dairy products.
  • Presence of immunodeficiency or impaired immune function.
  • Diagnosis of small intestinal bacterial overgrowth (SIBO).
  • Determined unsuitable by the investigator, for example, initiation of any new medication or therapy during the study period, particularly those related to memory impairment or cognitive decline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Probiotics

    Lacticaseibacillus paracasei PS23 one capsule daily for 12 weeks

    Dietary Supplement: Lacticaseibacillus paracasei

Interventions

06

What researchers measure

Primary outcomes

  1. Neuropsychological measures Changes in CANTAB® in 40 subjects after probiotic intervention

    Cambridge Neuropsychological Test Automated Battery (CANTAB®) includes computerized tests that are correlated to neural networks and have demonstrated high sensitivity in detecting changes in neuropsychological performance.

    Time frame: baseline to 12 weeks assessed

Secondary outcomes

  1. Changes in Chinese version of Trail Making Test (TMT) in 40 subjects after probiotic intervention

    The Trail Making Task (TMT) is a neuropsychological test consisting of two parts that assesses executive function, visual attention, speed of processing, and cognitive flexibility. In Part A, the participant connects 25 numbered circles in sequential numerical order (1 to 25) as quickly and accurately as possible. TMT-B with sequential numbers in the Chinese characters substituting for the English alphabetical sequence, replaced numbers and letters of the TMT-B by circles and squares with numbers, modified the TMT-B with the Chinese zodiacs substituting for the English alphabet

    Time frame: baseline to 12 weeks assessed

  2. Changes in Chinese version of Stroop color words test(SCWT) in 40 subjects after probiotic intervention

    The Stroop Color Words test (SCWT) was used to evaluate the dominant inhibition in executive function

    Time frame: baseline to 12 weeks assessed

  3. Changes in Geriatric Depression Scale in 40 subjects after probiotic intervention

    The Geriatric Depression Scale (GDS) is a screening tool for depression in older adults (55+), consisting of a short, yes/no questionnaire about feelings over the past week. Scores range between 0 and 30 points. Higher scores indicate more severe depressive symptoms.

    Time frame: baseline to 12 weeks assessed

  4. Changes in Anxiety Disorder Assessment (GAD-7) in 40 subjects after probiotic intervention

    The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include "not at all", "several days", "more than half the days" and "nearly every day"

    Time frame: baseline to 12 weeks assessed

  5. Changes in The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 (QLESQ-16) in 40 subjects after probiotic intervention

    The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 is a valid, reliable self-report instrument for assessing quality of life. The minimum raw score on the Q-LES-Q-16 is 14, and the maximum score is 70, higher scores mean a better outcome.

    Time frame: baseline to 12 weeks assessed

  6. Changes in Patient Global Impression scales of Improvement rated by patient (PGI-C) in 40 subjects after probiotic intervention

    The PGIC consists of one item taken from the clinical global impression and adapted to the patient. The minimum total score possible is 1 and the maximum total score possible is 7. Higher values represent a worse outcome.

    Time frame: baseline to 12 weeks assessed

  7. Changes in pTau-217 in 40 subjects after probiotic intervention

    Recent, research studies have shown that plasma levels of p-Tau 217 are elevated in AD patients1,2. Additionally, it has been demonstrated that plasma p-Tau 217 levels are increased in the early stages of the AD continuum and are correlated with amyloid-PET positivity.

    Time frame: baseline to 12 weeks assessed

  8. Changes in Plasma Aβ40 and Aβ42 in 40 subjects after probiotic intervention

    Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum

    Time frame: baseline to 12 weeks assessed

  9. Changes in Brain-derived neurotrophic factor (BDNF) in 40 subjects after probiotic intervention

    Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal survival and growth, serves as a neurotransmitter modulator, and participates in neuronal plasticity, which is essential for learning and memory.

    Time frame: baseline to 12 weeks assessed

  10. Changes in Glial Fibrillary Acidic Protein (GFAP) in 40 subjects after probiotic intervention

    Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer's disease (AD).

    Time frame: baseline to 12 weeks assessed

  11. Changes in Neurofilament Light (NfL) in 40 subjects after probiotic intervention

    Neurofilament light chain (NfL) is a structural protein that normally helps support the shape and function of brain cells. In Alzheimer's disease (AD), brain cells are damaged, which causes the brain to shrink (atrophy), and symptoms such as declining cognition to occur.

    Time frame: baseline to 12 weeks assessed

  12. Changes in Mandarin Subjective Cognitive Decline Scale (SCDS) in 40 subjects after probiotic intervention

    Self-reported questionnaire consisting of 14 items assessing perceived decline in memory, attention, language, planning, orientation, and other cognitive domains. Responses are typically rated on a Likert scale (e.g., 0 = "Never" to 4 = "Very frequently"), with total scores ranging from 0 to 56-higher scores indicate greater subjective cognitive complaints.

    Time frame: screening, baseline to 12 weeks assessed

07

Study locations

1 site
  • Graduate Institute of Sports Science, National Taiwan Sport University
    Taoyuan, 33301, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jan 2026, 3 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 3 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Aug 2026 → Jan 2026 and completion Dec 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 11, 2025
StartActual
Oct 17, 2025
Primary completionActual
Jan 31, 2026was Aug 2026
CompletionActual
Apr 2, 2026was Dec 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Sep 25, 2026
Primary completion
Aug 18, 2026→Jan 31, 2026 (actual)
Sep 25, 2026
Study completion
Dec 31, 2026→Apr 2, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Enrolling by invitation→Completed
    Primary completion Aug 18, 2026→Jan 31, 2026 (now actual)
    Study completion Dec 31, 2026→Apr 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07168824
Lead sponsor
Chi-Chang Huang
Collaborators
Bened Biomedical Co., Ltd.
Responsible party
Chi-Chang Huang (Dean of Research and Development, National Taiwan Sport University) — Sponsor-investigator
First posted
Sep 11, 2025
Start date
Oct 17, 2025
Primary completion
Jan 31, 2026
Completion
Apr 2, 2026
Last update
Sep 25, 2026

Study contacts

Chi-Chang Huang, PhD
principal investigator · National Taiwan Sport University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lacticaseibacillus paracasei

Start the discussion